Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Study of Combination of Temsirolimus (Torisel®) and Pegylated Liposomal Doxorubicin (PLD, Doxil®/ Caelyx®) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer

NCT00982631 is registered in ClinicalTrials.gov with Radboud University Medical Center as lead sponsor.

NCT NCT00982631
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00982631 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Study of Combination of Temsirolimus (Torisel®) and Pegylated Liposomal Doxorubicin (PLD, Doxil®/ Caelyx®) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer
Lead sponsor
Radboud University Medical Center
Phase
Phase 1
Overall status
Unknown status
Start date
June 30, 2009
Completion date
August 31, 2012
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced/recurrent breast cancer, endometrial cancer, ovarian cancer